Form 4: Director Janet Haugen Receives WST Stock Grant

West Pharmaceutical Services Director Janet B. Haugen acquired 791 restricted stock units as part of director compensation.

Summary

• Director Janet B. Haugen was granted 791 restricted stock units (RSUs) of West Pharmaceutical Services (WST) common stock.
• The transaction occurred on May 4, 2026, at a price of $0 per share.
• Following this transaction, the director's total beneficial ownership increased to 2,372.752 shares.
• The RSUs are scheduled to vest in full on the date of the next annual shareholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increase in total beneficial ownership by a member of the board.

Negatives

• None identified.

Risks

• Vesting of shares is contingent upon the director's continued service until the next annual shareholder meeting.

Future Outlook

The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with shareholder value in the pharmaceutical packaging and delivery systems sector.

Comparison to Industry Standards

• The grant of restricted stock units to directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.
• The vesting schedule tied to the annual shareholder meeting is a common retention mechanism for board members.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the 791 restricted stock units at the next annual shareholder meeting.

Key Dates

Keywords

West Pharmaceutical Services, WST, Form 4, Insider Trading, Director Compensation, Equity Grant